Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design

Abstract

Rationale

Over half of acute ischemic stroke patients have a low National Institutes of Health Stroke Scale of 0–5 and up to two-thirds may not appear clearly disabled at presentation. The efficacy of intravenous alteplase for the latter group is not known.

Aim

Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) was designed to evaluate the safety and efficacy of intravenous alteplase for the treatment of acute ischemic stroke with National Institutes of Health Stroke Scale 0–5 and without clearly disabling deficits.

Sample size estimates

A maximum of 948 subjects were required to test the superiority hypothesis with 80% power, according to a one-sided 0.025 level of significance.

Methods and design

PRISMS was a multicenter, randomized, double-blind, placebo-controlled phase 3b clinical trial. Patients were randomized to the active arm (intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo) or the control arm (intravenous alteplase placebo plus active oral aspirin dose of 325 mg).

Study outcome

The primary efficacy endpoint was favorable functional outcome, defined as a modified Rankin Scale score 0 or 1 assessed at 90-day postrandomization.

Keywords

Acute stroke therapy intervention ischemic stroke methodology protocols alteplase

Get full access to this article

View all access options for this article.

References

Reeves

Khoury

Alwell

et al.

Distribution of national institutes of health stroke scale in the Cincinnati/Northern Kentucky stroke study. Stroke 2013; 44: 3211–3213.

Dhamoon

Moon

Paik

et al.

Long-term functional recovery after first ischemic stroke. Stroke 2009; 40: 2805–2811.

Spokoyny

Raman

Ernstrom

et al.

Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients. J Stroke Cerebrovasc Dis 2015; 24: 1276–1281.

La Rosa

Khoury

Kissela

et al.

Eligibility for intravenous recombinant tissue-type plasminogen activator within a population. Stroke 2012; 43: 1591–1595.

Fischer

Baumgartner

Arnold

et al.

What is a minor stroke?

Stroke 2010; 41: 661–666.

Khatri

Conaway

Johnston

et al.

Ninety day outcome of ischemic stroke with mild symptoms at presentation: ASAP study subanalysis. Stroke 2012; 43: 560–562.

George

Tong

McGruder

et al.

Paul Coverdell National Acute Stroke Registry Surveillance – four states, 2005–2007. MMWR Surveill Summ 2009; 58: 1–23.

Smith

Fonarow

Reeves

et al.

Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines – stroke. Stroke 2011; 42: 3110–3115.

Messé

Khatri

Reeves

et al.

Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. Neurology 2016; 87: 1565–1574.

10.

Asdaghi

Romano

Wang

et al.

Abstract TP315: predictors of thrombolysis administration in patients with minor stroke or TIA in the Florida Puerto Rico collaboration to reduce stroke disparities (FL-PR CReSD) Study. Stroke 2016; 47. ATP315, originally published 16 February 2016.

11.

Stecksén

Asplund

Appelros

et al.

Thrombolytic therapy rates and stroke severity. Stroke 2012; 43: 536–538.

12.

Emberson

Lees

Lyden

et al.

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–1935.

13.

Khatri

Tayama

Cohen

et al.

Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third international stroke trial (IST-3): a post hoc analysis. Stroke 2015; 46: 2325–2327.

14.

Demaerschalk

Kleindorfer

Adeoye

et al.

Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke 2016; 47: 581–641.

15.

Levine

Khatri

Broderick

et al.

Re-examining Acute Eligibility for Thrombolysis (TREAT) task force. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria. Stroke 2013; 44: 2500–2505.

16.

Zhao

Tayama

Yeatts

. Comparison of statistical and operational properties of subject randomization procedures for large multicenter clinical trial treating medical emergencies. Contemp Clin Trials 2015; 41: 211–218.

17.

Zhao

Weng

. Block urn design – a new randomization algorithm for sequential trials with two or more treatments and balanced or unbalanced allocation. Contemp Clin Trials 2011; 32: 953–961.

18.

Wei

. The adaptive biased coin design for sequential experiments. Ann Stat 1978; 6: 92–100.

19.

Efron

. Forcing sequential experiments to be balanced. Biometrika 1971; 58: 403–417.

20.

Tilley

Marler

Geller

et al.

Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke 1996; 27: 2136–2142.

21.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.

22.

Khatri

Kleindorfer

Yeatts

et al.

Strokes with minor symptoms: an exploratory analysis of the NINDS rt-PA trials. Stroke 2010; 41: 2581–2586.

23.

Sandercock

Wardlaw

Lindley

et al.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352–2363.

24.

Jauch

Saver

Adams

et al.

Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013; 44: 870–947.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.30 MB